Literature DB >> 31186792

Surgical treatment of early tongue squamous cell carcinoma and patient survival.

Lansheng Zhu1, Yanling Wang1, Rui Li2, Aiqun Liu1, Xiaoping Zhang1, Chunran Zuo1, Xiaoting Xu1.   

Abstract

Surgical options for treating early tongue squamous cell carcinoma and patient survival were explored. Clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM from June, 2010 to June, 2013 were retrospectively analyzed. According to adopted treatment plan, the patients were divided into 3 groups: 42 patients in surgical therapy alone group, 46 patients in preoperative radiotherapy group, and 40 patients in postoperative radiotherapy group. Statistical analysis was performed on the general data of patients and clinical records, as well as the 5-year survival rate and recurrence rate. The overall 5-year survival rate for all patients was 86.7% (111/128), and the 5-year disease-specific survival rate was 88.8% (111/125). In the individual groups, the 5-year survival rate and the 5-year disease-specific survival rate were 91.3% (84/92) and 91.3% (84/92), respectively, in the surgical therapy alone group 76.9% (10/13) and 83.3% (10/12), respectively, in the preoperative radiotherapy group, and 73.9% (17/23) and 81.0% (17/21), respectively, in the postoperative radiotherapy group. There were no statistically significant differences in 5-year survival rate (χ2=5.990, P=0.051) and 5-year disease-specific survival rate (χ2=2.223, P=0.329) among the three groups. In total, there were 25 cases of recurrence during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 6 cases of metastasis, and the metastatic rate was 4.7%. There were no statistically significant differences in recurrence rate and metastatic rate among the three groups. Compared with surgical therapy alone, radiotherapy combined with surgical therapy neither improved 5-year survival rate nor reduced recurrence rate. Therefore, surgical therapy alone is suggested to be the preferred option for treating early tongue squamous cell carcinoma.

Entities:  

Keywords:  early tongue squamous cell carcinoma; surgical treatment; survival

Year:  2019        PMID: 31186792      PMCID: PMC6507335          DOI: 10.3892/ol.2019.10271

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Tongue cancer is a common cancer in the mouth, accounting for 30–50% of all oral cancers. The most common type of tongue cancer is squamous cell carcinoma. Statistics indicated that the incidence is significantly higher for men compared to women (1,2). As the population in China is aging, the incidence of tongue cancer among elderly people is increasing year by year. Because blood vessels and lymphatic vessels are rich in the tongue and the tongue muscle is frequently squeezed due to structural reasons, tongue squamous cell carcinoma is prone to metastasize even in its early stage and therefore has a poor prognosis (3,4). Early diagnosis and early treatment of tongue squamous cell carcinoma is the key to patient recovery. At present, commonly used clinical treatment options for tongue squamous cell carcinoma are surgery, chemotherapy, radiotherapy and comprehensive treatment. However, therapeutic outcomes of patients with early tongue squamous cell carcinoma using various surgical protocols are still open to debate, and few related studies can be found in literature (5,6). In this study, retrospective analysis was performed on clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM (Zhengzhou, China) from June, 2010 to June, 2013. Therapeutic outcomes of these patients with early tongue squamous cell carcinoma were compared between three treatment options, i.e. surgical therapy alone, preoperative radiotherapy and postoperative radiotherapy. This study aimed to provide a more precise treatment plan for patients with tongue cancer in different stages and to improve treatment.

Materials and methods

Subjects

Clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM from June, 2010 to June, 2013 were retrospectively analyzed. According to adopted treatment plan, the patients were divided into 3 groups: 92 patients in surgical therapy alone group, 13 patients in preoperative radiotherapy group, and 23 patients in postoperative radiotherapy group. The study was approved by the Εthics Committee of Henan Province Hospital of TCM. Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians.

Inclusion criteria

Patients who met the following criteria were eligible for the study: i) Patients who were diagnosed to have primary tongue squamous cell carcinoma in the early stages (cT1-2N0); ii) patients who received treatment for the first time; iii) patients whose lesion was on the forward portion of the tongue; and iv) patients who had complete clinical records.

Exclusion criteria

Patients who met the following criteria were excluded from this study: i) patients who also had other kinds of primary cancers; ii) patients who also had lymph node metastasis; iii) patients who underwent cervical lymph node dissection; iv) patients with pathologically positive surgical margins; and v) patients who had a survival of less than two months.

Treatment procedures

Patients in the surgical therapy alone group underwent primary lesion resection, which was performed by physicians who had been in clinical practice for more than 5 years. The diseased tissue was removed along a cut edge 1–2 cm away from the lesion, resulting in cancer-free resection margins. Patients in the preoperative radiotherapy group received preoperative radiotherapy in addition to the above-mentioned primary lesion resection. First, the lesion location was determined by imaging techniques and the results of clinical diagnosis. Then, radiotherapy was given by external beam radiation alone or combination of external beam radiation and internal radiation by inserting a radiation source inside the tissue (combined radiation). The total dose of external beam radiation therapy was 50–72 Gy (64.5±4.7 Gy), and the energy range of external radiation source was 5–6 MV. The total dose of combined radiation therapy was <60 Gy. Radiotherapy was completed within 15–70 days before surgery. The radiotherapy protocol in the postoperative radiotherapy group was similar to that in the preoperative radiotherapy group mentioned above. The total dose of external beam radiation therapy was 50–72 Gy (66.1±5.3 Gy), and the total dose of combined radiation therapy was <70 Gy. Radiotherapy was completed within 15–75 days after surgery.

Research method

Statistical analysis was performed on patient general data and clinical records, as well as the patient's 5-year survival rate and recurrence rate. The general data and clinical records included sex ratio, age distribution, disease course (referring to the time from onset to operation), pathological type, and clinical stage. The statistics of patients' clinical data were obtained by follow-up. The starting time of follow-up is the discharge time of patients, and the end time was 30 June 2018 or the death of patients. The forms of follow-up mainly include questionnaire, telephone, and outpatient follow-up.

Statistical analysis

Data were processed using SPSS 19.0 (IBM Corp., Armonk, NY, USA) statistics software. The χ2 test was used for comparison of quantitative data which were expressed as (mean ± SD). The t-test was used for comparison of measurement data. Differences in survival rate between groups were obtained by using the Kaplan-Meier test and log rant test. Results of multivariate analysis were obtained by using the COX test. A difference was considered statistically significant at P<0.05.

Results

Comparison of patient general data

As shown in Table I, there were no statistically significant differences in sex ratio, age distribution, disease course, pathological type, clinical stage, and tumor location among the three groups.
Table I.

Comparison of patient general data.

VariantSurgical therapy alone group (n=92)Preoperative radiotherapy group (n=13)Postoperative radiotherapy group (n=23)χ2P-value
Sex
  Male568150.1460.929
  Female365  8
Age (years)53.1±6.955.4±7.154.9±7.30.6630.794
Smoking0.0240.988
  Yes51713
  No41610
Disease course
  >6 months526110.9030.637
  ≤6 months40712
Pathological type
  Well differentiated709160.4700.791
  Moderately differentiated143  5
  Poorly differentiated  81  2
Clinical stage
  Stage I538  92.7870.248
  Stage II39514
Tumor location
  Lateral tongue659170.0760.963
  Ventral tongue213  4
  Dorsal tongue  61  2

Comparison of survival rate

The overall 5-year survival rate for all patients was 86.7% (111/128), that of stage I was 88.5% (62/70), and that of stage II was 84.5% (49/58). The 5-year disease-specific survival rate was 88.8% (111/125), which was 91.2% (62/68) in stage I, and 85.9% (49/57) in stage II. In individual groups, the 5-year survival rate and the 5-year disease-specific survival rate were 91.3% (84/92) and 91.3% (84/92), respectively, in the surgical therapy alone group 76.9% (10/13) and 83.3% (10/12), respectively, in the preoperative radiotherapy group, and 73.9% (17/23) and 81.0% (17/21), respectively, in the postoperative radiotherapy group. There were no statistically significant differences in 5-year survival rate (χ2=5.990, P=0.051) and 5-year disease-specific survival rate (χ2=2.223, P=0.329) among the three groups. The results are shown in Figs. 1 and 2.
Figure 1.

Disease-specific survival rates of patients in the three groups.

Figure 2.

Survival rates of patients in the three groups.

Comparison of recurrence rate and metastatic rate in the three groups

As shown in Table II, there were 25 cases of recurrence in total during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 5 cases of metastasis, and the metastatic rate was 4.7%. There were no statistically significant differences in recurrence rate and metastatic rate among the three groups.
Table II.

Comparison of recurrence rate and metastatic rate in the three groups.

VariantSurgical therapy alone groupPreoperative radiotherapy groupPostoperative radiotherapy groupχ2P-value
Patient number921323
Recurrence18  2  50.2820.868
Local recurrence11  1  30.2250.880
Regional recurrence  7  1  20.0870.958
Metastasis  3  1  10.7430.690

Discussion

Surgical therapy is the primary treatment option for tongue cancer, while radiotherapy and chemotherapy are adjuvant therapy. Patients rarely receive radiotherapy or chemotherapy alone for tongue cancer. Radiotherapy and chemotherapy have proven systemic toxic side effects, and physicians are unable to reach a consensus on whether they have an impact on patient survival (7,8). All the subjects in this study underwent surgical treatment and included the majority of patients diagnosed with tongue squamous cell carcinoma. This study aimed to provide a scientific reference for the treatment of tongue cancer. Patients with tongue cancer have a poor prognosis. The 5-year survival rate is about 27% for mid-stage/late stage patients. The subjects included in this study were all patients with early tongue squamous cell carcinoma, for whom few research reports appear in literature. In this study, the overall 5-year survival rate and the 5-year disease-specific survival rate were 86.7 and 88.8%, respectively, which were all higher compared with similar studies in literature (9,10). The causes of this exceptional result could be that i) the patients selected in this study had milder symptoms or ii) continuous advancement of medical technology led to overall improvement of treatment outcomes such as overall survival rate of patients with early tongue squamous cell carcinoma (11,12). There were no statistically significant differences in 5-year survival rate among patients in the three groups. To get more accurate results, a larger sample size may be needed because the number of subjects in this study reached the threshold. However, some studies have pointed out that (13) functional and aesthetic deficiencies caused by radical surgery can reduce the quality of life of patients, so conservative treatment is better than radical treatment for elderly patients aged over 60 years. Therefore, the average age of patients selected into this study is lower than 60 years. The main purpose of preoperative radiotherapy was to attenuate tumor cell activity and reduce the risk of tumor cell implantation into benign lesions, thereby lowering cancer recurrence rate and metastatic rate. In addition, preoperative radiotherapy can significantly decrease tumor cell volume, making the surgical procedures a little easier to perform. The postoperative radiotherapy was to give patients more precise radiotherapy in terms of location and dose because related information can be more accurately obtained after surgery and verified using imaging techniques. Postoperative radiotherapy was expected to improve the treatment (13,14). In this study, it was found that adjuvant radiotherapy did not improve the 5-year survival rate of patients with early tongue cancer. Our finding was opposite to reports in literature (15,16), and the possible reason could be that the recruited patients with early tongue cancer had relatively milder symptoms. Surgery caused great tissue injury to the patient's body. In addition, systemic side effects of radiotherapy can seriously affect the immune system. Surgical therapy alone would be enough to achieve the treatment goal. In order to avoid overtreatment and reduce complexity of treatment procedures, the authors suggest that surgical therapy alone be adopted to treat patients with early tongue squamous cell carcinoma. There were 25 cases of recurrence in total during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 6 cases of metastasis, and the metastatic rate was 4.7%. It was found that neither preoperative radiotherapy nor postoperative radiotherapy can reduce the 5-year recurrence rate. The possible reason could be that both preoperative radiotherapy and postoperative radiotherapy had a balance between effectiveness in killing cancer cells and aggressiveness in causing damage to the body (17–19). Radiotherapy caused great damage to the patient's body, and was probably too aggressive for treating early tongue squamous cell carcinoma. Preoperative and postoperative radiotherapy should be avoided as much as possible. In conclusion, compared with surgical therapy alone, radiotherapy combined with surgical therapy neither improved 5-year survival rate nor reduced recurrence rate. Therefore, surgical therapy alone is suggested to be the preferred option for treating patients with early tongue squamous cell carcinoma.
  18 in total

1.  Activin A immunoexpression as predictor of occult lymph node metastasis and overall survival in oral tongue squamous cell carcinoma.

Authors:  Natalie Kelner; Priscila Campioni Rodrigues; Andreia Bufalino; Felipe Paiva Fonseca; Alan Roger dos Santos-Silva; Marcia Cristina Costa Miguel; Clóvis Antonio Lopes Pinto; Adriana Franco Paes Leme; Edgard Graner; Tuula Salo; Luiz Paulo Kowalski; Ricardo D Coletta
Journal:  Head Neck       Date:  2014-04-03       Impact factor: 3.147

2.  Predictors of prognosis for squamous cell carcinoma of oral tongue.

Authors:  Shivakumar Thiagarajan; Sudhir Nair; Deepa Nair; Pankaj Chaturvedi; Shubhadra V Kane; Jai Prakash Agarwal; Anil K D'Cruz
Journal:  J Surg Oncol       Date:  2014-03-12       Impact factor: 3.454

3.  Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Authors:  Ezra E W Cohen; Theodore G Karrison; Masha Kocherginsky; Jeffrey Mueller; Robyn Egan; Chao H Huang; Bruce E Brockstein; Mark B Agulnik; Bharat B Mittal; Furhan Yunus; Sandeep Samant; Luis E Raez; Ranee Mehra; Priya Kumar; Frank Ondrey; Patrice Marchand; Bettina Braegas; Tanguy Y Seiwert; Victoria M Villaflor; Daniel J Haraf; Everett E Vokes
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

4.  Prognostic factors and outcomes for salvage surgery in patients with recurrent squamous cell carcinoma of the tongue.

Authors:  Mitsuo Goto; Nobuhiro Hanai; Taijiro Ozawa; Hitoshi Hirakawa; Hidenori Suzuki; Ikuo Hyodo; Takeshi Kodaira; Tetsuya Ogawa; Yasushi Fujimoto; Akihiro Terada; Hisakazu Kato; Yasuhisa Hasegawa
Journal:  Asia Pac J Clin Oncol       Date:  2013-08-02       Impact factor: 2.601

5.  A new surgical strategy for treatment of tongue squamous cell carcinoma based on anatomic study with preliminary clinical evaluation.

Authors:  Zhen-Hu Ren; Han-Jiang Wu; Sheng Zhang; Kai Wang; Zhao-Jian Gong; Zhi-Jing He; Jie Peng
Journal:  J Craniomaxillofac Surg       Date:  2015-08-05       Impact factor: 2.078

6.  Early Oral Tongue Squamous Cell Carcinoma: Sampling of Margins From Tumor Bed and Worse Local Control.

Authors:  Jessica H Maxwell; Lester D R Thompson; Margaret S Brandwein-Gensler; Bernhard G Weiss; Martin Canis; Bibianna Purgina; Arpan V Prabhu; Chi Lai; Yongli Shuai; William R Carroll; Anthony Morlandt; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Robert L Ferris; Raja Seethala; Simion I Chiosea
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-12       Impact factor: 6.223

7.  The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma.

Authors:  Manikkath Aparna; Lakshmi Rao; Vijayanarayana Kunhikatta; Raghu Radhakrishnan
Journal:  J Oral Pathol Med       Date:  2014-09-12       Impact factor: 4.253

8.  Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.

Authors:  Jian Meng; Qian-ping Gu; Qing-fei Meng; Jie Zhang; Zhi-ping Li; Ya-meng Si; Wei Guo; Qian-wei Zhuang
Journal:  Cell Biochem Biophys       Date:  2014-01       Impact factor: 2.194

9.  Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium.

Authors:  Tatiana Natasha Toporcov; Ariana Znaor; Zuo-Feng Zhang; Guo-Pei Yu; Deborah M Winn; Qingyi Wei; Marta Vilensky; Thomas Vaughan; Peter Thomson; Renato Talamini; Neonila Szeszenia-Dabrowska; Erich M Sturgis; Elaine Smith; Oxana Shangina; Stephen M Schwartz; Stimson Schantz; Peter Rudnai; Lorenzo Richiardi; Heribert Ramroth; Mark P Purdue; Andrew F Olshan; José Eluf-Neto; Joshua Muscat; Raquel Ajub Moyses; Hal Morgenstern; Ana Menezes; Michael McClean; Keitaro Matsuo; Dana Mates; Tatiana V Macfarlane; Jolanta Lissowska; Fabio Levi; Philip Lazarus; Carlo La Vecchia; Pagona Lagiou; Sergio Koifman; Kristina Kjaerheim; Karl Kelsey; Ivana Holcatova; Rolando Herrero; Claire Healy; Richard B Hayes; Silvia Franceschi; Leticia Fernandez; Eleonora Fabianova; Alexander W Daudt; Otávio Alberto Curioni; Luigino Dal Maso; Maria Paula Curado; David I Conway; Chu Chen; Xavier Castellsague; Cristina Canova; Gabriella Cadoni; Paul Brennan; Stefania Boccia; José Leopoldo Ferreira Antunes; Wolfgang Ahrens; Antonio Agudo; Paolo Boffetta; Mia Hashibe; Yuan-Chin Amy Lee; Victor Wünsch Filho
Journal:  Int J Epidemiol       Date:  2015-01-22       Impact factor: 7.196

10.  Oral tongue squamous cell carcinoma in young women: a matched comparison-do outcomes justify treatment intensity?

Authors:  Ryan P Goepfert; Eric J Kezirian; Steven J Wang
Journal:  ISRN Otolaryngol       Date:  2014-03-10
View more
  1 in total

1.  Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines.

Authors:  Aisha A H Al-Jamaei; Jan G A M de Visscher; Tymour Forouzanfar; Ruud H Brakenhoff; C René Leemans; Arwen Stikvoort; Behrouz Zandieh-Doulabi; Marco N Helder
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-02       Impact factor: 4.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.